What Are Bioavailability and Bioequivalence, and Why Do They Matter?
Do two medicines containing the same active ingredient always produce the same effect in a patient? The intuitive answer seems to be yes, but the reality is more subtle. What determines a drug’s effect is not only the amount of active ingredient it contains, but how much of that ingredient is absorbed in the body and how quickly. This is precisely where the concepts of bioavailability and bioequivalence come into play, forming one of the cornerstones of modern drug development.
What is bioavailability?
Bioavailability describes the extent and the rate at which the active ingredient in a medicine reaches the systemic circulation. There are two distinct dimensions here. The first is the extent of absorption, meaning how much of the administered dose actually enters the bloodstream. The second is the rate of absorption, meaning how quickly this transfer takes place.
These two dimensions are not abstract notions; they are measurable quantities. After a medicine is taken, the concentration of the active ingredient in the blood rises over time, reaches a peak, and then begins to fall. When this change is plotted on a graph, the result is a typical concentration-time curve. The total area beneath this curve reflects how much the body has been exposed to the drug overall and is the measure of the extent of absorption; known as the area under the curve, or AUC, this quantity is the numerical expression of total exposure. The highest point the curve reaches represents the peak concentration in the blood; referred to as the maximum concentration, or Cmax, this value shows the drug’s peak level in the blood. The time needed to reach this highest point reflects how fast absorption occurs and is expressed as the time to maximum concentration, or Tmax.
In short, bioavailability quantifies the difference between simply saying “the drug entered the body” and saying “the drug is ready at its site of action, in the right amount and at the right time.”
What is bioequivalence?
Bioequivalence is the situation in which there is no meaningful difference between the bioavailabilities of two medicines containing the same active ingredient. If two products deliver the active ingredient to the body at the same rate and to the same extent, they are expected to produce the same therapeutic effect. In this case the products are considered therapeutically equivalent and can be used interchangeably.
The assumption underlying this approach is clear: a drug’s therapeutic effect depends on the concentration of the active ingredient at its site of action. Therefore, if two products produce the same concentration profile in the blood, their clinical effects are also expected to be the same. Bioequivalence studies are built on this logic and compare two products not directly through clinical outcomes, but through the active ingredient profile in the blood.
One distinction must be made clear here. The fact that two products contain the same amount of the same active ingredient does not, on its own, guarantee that they will behave equivalently. Factors such as tablet hardness, the excipients used, and the manufacturing method can change how the active ingredient dissolves and is absorbed in the body. For this reason equivalence is not accepted as an assumption; it is proven by measurement.
Why does it matter?
The importance of bioavailability and bioequivalence becomes apparent both in newly developed originator drugs and in generic drugs.
When an originator drug is being developed, different formulations are tried; when moving between a tablet, a capsule, or a different dosage form, it must be shown that the products behave in the same way. These comparisons during development are carried out through bioavailability studies.
For generic drugs, the matter concerns public health and access to medicines directly. When the patent of an originator drug expires, generic products containing the same active ingredient can enter the market and significantly lower the cost of treatment. However, for these products to be used safely, they must be shown to be of the same quality, efficacy, and safety as the originator drug. What provides this assurance is the bioequivalence study. Once a generic medicine has proven that it is bioequivalent to the reference originator product, it becomes a reliable and affordable option for the physician and the patient.
These studies are therefore not merely a regulatory requirement. They are the scientific guarantee that the medicine reaching the patient will truly produce the expected effect.
What does a bioavailability and bioequivalence study measure?
In bioavailability and bioequivalence studies the underlying logic is this: the test product and the reference product are compared under controlled conditions. After the products are administered to the participants, blood samples are taken at defined time intervals and the concentration of the active ingredient in each sample is measured. From these measurements a concentration-time curve is produced for each product.
The areas under the curve and the peak concentration values of the two products are then compared. If these values fall within predefined acceptance limits of one another, the products are considered bioequivalent. How these acceptance limits are set, how the study is designed, and how the results are evaluated statistically are subjects in their own right and will be addressed in the following articles of this series.
At this point a critical detail comes to the fore. The result of a bioavailability and bioequivalence study depends on how accurately the concentration of the active ingredient in the blood is measured. Without validated analytical methods that can reliably measure even very low concentrations, even the best-designed study loses its meaning. For this reason the quality of the bioanalytical measurement lies at the foundation of the entire process.
NanoTox’s role in this field
As a bioavailability and bioequivalence center authorized by the Turkish Medicines and Medical Devices Agency, NanoTox meets the scientific requirements of these studies. The LC-MS/MS infrastructure in our laboratory and our experience in bioanalytical method validation make it possible to measure the concentrations of the active ingredient in the blood accurately and reproducibly, even at low levels. The results thus obtained rest on a solid foundation, both scientifically and from a regulatory standpoint.
In the articles that follow, we will examine one by one how bioavailability and bioequivalence studies are designed, why the variability of the results matters, how the regulatory framework operates, and where bioanalytical method validation stands within this process.